Financial reports
10-Q
2018 Q3
Quarterly report
13 Nov 18
10-Q
2018 Q2
Quarterly report
15 Oct 18
10-Q
2018 Q1
Quarterly report
15 Oct 18
10-K/A
2017 FY
Annual report (amended)
15 Oct 18
NT 10-Q
Notice of late quarterly filing
14 May 18
10-K
2017 FY
Annual report
2 Apr 18
10-Q
2017 Q3
Quarterly report
7 Nov 17
10-Q
2017 Q2
Quarterly report
14 Aug 17
Current reports
8-K
Bankruptcy or Receivership
25 Mar 19
8-K
MabVax Therapeutics and Oncotelic Enter into Merger Discussions
4 Jan 19
8-K
Entry into a Material Definitive Agreement
20 Nov 18
8-K
Regulation FD Disclosure
19 Oct 18
8-K
MabVax Therapeutics Audited Financial Statements Reinstated
16 Oct 18
8-K
Entry into a Material Definitive Agreement
9 Jul 18
8-K
MabVax Therapeutics Receives Nasdaq Delist Determination
5 Jul 18
8-K
MabVax Therapeutics Grants Exclusive Sublicense to Y-mAbs Therapeutics for Patented Neuroblastoma Vaccine
3 Jul 18
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Jul 18
8-K
MabVax Therapeutics Receives Superseding Letter Related to the Late Filing of Form 10-Q
28 Jun 18
Registration and prospectus
RW
Registration withdrawal request
19 Sep 19
15-12G
Securities registration termination
29 Mar 19
S-1
IPO registration
20 Nov 18
25-NSE
Exchange delisting
27 Sep 18
D
$860K in equity, sold $830K, 11 investors
15 May 18
D
$2.75M in equity / options / securities to be acquired, sold $2.75M, 13 investors
13 Feb 18
RW WD
Withdrawal of registration withdrawal request
2 Feb 18
RW WD
Withdrawal of registration withdrawal request
2 Feb 18
RW
Registration withdrawal request
30 Jan 18
RW
Registration withdrawal request
30 Jan 18
Proxies
DEF 14A
Definitive proxy
13 Nov 17
PRE 14A
Preliminary proxy
24 Oct 17
DEF 14A
Definitive proxy
6 Sep 17
PRE 14A
Preliminary proxy
24 Aug 17
DEF 14A
Definitive proxy
3 May 17
DEF 14A
Definitive proxy
31 May 16
PRE 14A
Preliminary proxy
17 May 16
DEFA14A
Additional proxy soliciting materials
31 Jul 15
DEF 14A
Definitive proxy
27 Jul 15
PRE 14A
Preliminary proxy
14 Jul 15
Other
SEC STAFF
SEC staff action: Order
22 Apr 19
SEC STAFF
SEC staff action: Order
22 Apr 19
SEC STAFF
SEC staff action: Order
22 Apr 19
SEC STAFF
SEC staff action: Order
22 Apr 19
CT ORDER
Confidential treatment order
22 Oct 18
EFFECT
Notice of effectiveness
27 Jul 17
CORRESP
Correspondence with SEC
25 Jul 17
EFFECT
Notice of effectiveness
14 Jun 17
CORRESP
Correspondence with SEC
12 Jun 17
UPLOAD
Letter from SEC
9 Jun 17
Ownership
SC 13G/A
Mabvax Therapeutics Holdings, Inc.
9 May 19
SC 13G
Mabvax Therapeutics Holdings, Inc.
6 Aug 18
SC 13D/A
Mabvax Therapeutics Holdings, Inc.
25 Jul 18
4/A
PAUL V MAIER
4 Apr 18
4/A
Kenneth M Cohen
4 Apr 18
4
Kenneth M Cohen
3 Apr 18
4
PAUL V MAIER
3 Apr 18
4
PAUL W MAFFUID
3 Apr 18
4
GREGORY P HANSON
3 Apr 18
4
JOHN DAVID HANSEN
3 Apr 18